Page last updated: 2024-11-12

2-((3-chloroethyl)-3-nitrosoureido)glucopyranose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID12600646
CHEMBL ID2094020
SCHEMBL ID11409480
MeSH IDM0176719

Synonyms (8)

Synonym
chlorzotocin
70866-07-8
2-((3-chloroethyl)-3-nitrosoureido)glucopyranose
d-glucopyranose, 2-(((2-(chloroethyl)nitrosoamino)carbonyl)amino)-2-deoxy-
2-(((2-(chloroethyl)nitrosoamino)carbonyl)amino)-2-deoxy-d-glucopyranose
CHEMBL2094020
SCHEMBL11409480
1-(2-chloroethyl)-1-nitroso-3-[(3r,4r,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (54)

Assay IDTitleYearJournalArticle
AID23276Partition coefficient (logP)1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Antitumor structure-activity relations. Nitrosoureas vs. L-1210 leukemia.
AID25750Pharmacokinetic parameter k2 was determined1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
An analysis of 1-(2-chloroethyl)-1-nitrosourea activity at the cellular level.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID134226Toxicity against L-1210 leukemia cells in mice after intraperitoneal administration, activity is expressed as LD101980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Antitumor structure-activity relations. Nitrosoureas vs. L-1210 leukemia.
AID1123144Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse assessed as tumor growth inhibition at 24 mg/kg, ip administered on day 1 post-tumor cell implantation1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
L-Chlorozotocin.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID409955Inhibition of mouse liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1149527Antitumor activity against mouse advanced Lewis lung carcinoma allografted in ip dosed BDF1 mouse assessed as increase in host lifespan administered as single dose on day 6 or 7 post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID23772Half life was measured at pH 71988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1123143Toxicity in ip dosed CDF1 mouse1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
L-Chlorozotocin.
AID135724Oncostatic index (median survival time (treated)/median survival time (control) x 100); Over 50% cured.1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antitumor evaluation of some nitrosourea and nitrogen mustard amino acid derivatives.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID125581Tested for 3 log kill of leukemia cells1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Antitumor structure-activity relations. Nitrosoureas vs. L-1210 leukemia.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1149525Antitumor activity against mouse advanced Lewis lung carcinoma allografted in ip dosed BDF1 mouse assessed as complete regression of established tumor administered as single dose on day 6 or 7 post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID15821Alkylating activity was determined1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
An analysis of 1-(2-chloroethyl)-1-nitrosourea activity at the cellular level.
AID130098Dose range for antitumor activity against leukemia L1210 in mice.1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antitumor evaluation of some nitrosourea and nitrogen mustard amino acid derivatives.
AID152565Mean value for the exposure for P388 to the drug for a period of 40 min at pH 7.4 and 37 degree1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
An analysis of 1-(2-chloroethyl)-1-nitrosourea activity at the cellular level.
AID1123141Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse assessed as dose causing 50% 60-day host survival at 24 mg/kg, ip administered on day 1 post-tumor cell implantation1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
L-Chlorozotocin.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID15912Carbamoylating activity was determined1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
An analysis of 1-(2-chloroethyl)-1-nitrosourea activity at the cellular level.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1149523Ratio of ED50 for antitumor activity against mouse L1210 cells allografted in ip dosed mouse to LD10 for mouse1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID152566Mean value for the exposure for P388 to the drug for a period of 60 min1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
An analysis of 1-(2-chloroethyl)-1-nitrosourea activity at the cellular level.
AID23481Partition coefficient (logP)1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
An analysis of 1-(2-chloroethyl)-1-nitrosourea activity at the cellular level.
AID133623Optimum dose for antitumor activity against leukemia L1210 in mice1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antitumor evaluation of some nitrosourea and nitrogen mustard amino acid derivatives.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1149521Antitumor activity against mouse early Lewis lung carcinoma allografted in ip dosed BDF1 mouse assessed as disease cure administered as single dose on 1 or 2 days post-tumor implantation measured for 80 days post-drug treatment1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1123142Therapeutic index, ratio of ED50 for antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse to LD10 for CDF1 mouse1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
L-Chlorozotocin.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID409953Inhibition of mouse liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1149427Antitumor activity against mouse advanced Lewis lung carcinoma allografted in BDF1 mouse assessed as complete regression of established tumor at 13 mg/kg, ip administered as single dose on 7th day post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID134731Median lethal dose in L1210 (murine luekemia) inoculated mice.1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antitumor evaluation of some nitrosourea and nitrogen mustard amino acid derivatives.
AID1149526Antitumor activity against mouse advanced Lewis lung carcinoma allografted in ip dosed BDF1 mouse assessed as disease cure administered as single dose on day 6 or 7 post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1149522Antitumor activity against mouse early Lewis lung carcinoma allografted in ip dosed BDF1 mouse administered as single dose on 1 or 2 days post-tumor implantation measured for 80 days post-drug treatment1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID235251Therapeutic index in L1210 (murine leukemia) inoculated mice.1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antitumor evaluation of some nitrosourea and nitrogen mustard amino acid derivatives.
AID1123140Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse assessed as increase in host life span at 24 mg/kg, ip administered on day 1 post-tumor cell implantation1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
L-Chlorozotocin.
AID1149410Antitumor activity against mouse advanced Lewis lung carcinoma allografted in BDF1 mouse assessed as increase in host life span at 13 mg/kg, ip administered as single dose on 7th day post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1123138Toxicity in ip dosed CDF1 mouse assessed as circulating white blood cell count1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
L-Chlorozotocin.
AID1149462Antitumor activity against mouse advanced Lewis lung carcinoma allografted in BDF1 mouse assessed as disease cure at 13 mg/kg, ip administered as single dose on 7th day post-tumor implantation measured for 80 days post-drug treatment1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1123139Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse assessed as median day of death at 24 mg/kg, ip administered on day 1 post-tumor cell implantation (Rvb = 8 days)1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
L-Chlorozotocin.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (75.00)18.7374
1990's1 (12.50)18.2507
2000's1 (12.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.87 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]